Bibliography
Export 9 results:
Filters: Author is Champlin,R. [Clear All Filters]
Microbial contamination of hematopoietic progenitor cell products: clinical outcome. Bone Marrow Transplant. 2007;40(4):5.
Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: donor type matters. Blood. 2004;103(12):4674-80.
Donor lymphocyte apheresis for adoptive immunotherapy compared with blood stem cell apheresis. Journal of Clinical Apheresis. 2001;16(2):82-7.
Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 1999;94(4):1465-70.
Blood stem cell procurement: donor safety issues. Bone Marrow Transplant. 1998;21 Suppl 3:S35-9.
Allogeneic blood stem cell transplantation: considerations for donors. Blood. 1997;90(3):903-8.
Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures.[Erratum appears in Transfusion 1997 Jan;37(1):109]. Transfusion. 1996;36(7):590-5.
Delayed effects of rhG-CSF mobilization treatment and apheresis on circulating CD34+ and CD34+ Thy-1dim CD38- progenitor cells, and lymphoid subsets in normal stem cell donors for allogeneic transplantation. Bone Marrow Transplantation. 1996;18(6):1073-9.
Transient neutropenia in normal donors after G-CSF mobilization and stem cell apheresis. British Journal of Haematology. 1996;94(1):155-8.